Spark Therapeutics, Inc. (ONCE) Stock Rating Lowered by Zacks Investment Research
Spark Therapeutics, Inc. (NASDAQ:ONCE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday.
According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “
A number of other brokerages have also commented on ONCE. Cantor Fitzgerald restated a “buy” rating and issued a $94.00 price target on shares of Spark Therapeutics in a report on Friday, November 4th. J P Morgan Chase & Co restated a “buy” rating on shares of Spark Therapeutics in a report on Monday, November 7th. Vetr lowered Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 price target on the stock. in a report on Tuesday. Chardan Capital restated a “neutral” rating on shares of Spark Therapeutics in a report on Tuesday, December 6th. Finally, Jefferies Group reiterated a “hold” rating and set a $47.00 target price on shares of Spark Therapeutics in a report on Tuesday, December 6th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. Spark Therapeutics has an average rating of “Hold” and an average target price of $60.69.
Spark Therapeutics (NASDAQ:ONCE) opened at 57.13 on Friday. Spark Therapeutics has a 12 month low of $21.20 and a 12 month high of $65.99. The company has a 50-day moving average of $53.39 and a 200 day moving average of $55.20. The stock’s market capitalization is $1.76 billion.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by $0.06. The firm earned $1.30 million during the quarter, compared to the consensus estimate of $1.26 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.70) earnings per share. On average, equities research analysts anticipate that Spark Therapeutics will post ($4.13) earnings per share for the current fiscal year.
In other news, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $60.30, for a total value of $603,000.00. Following the transaction, the insider now owns 210,000 shares of the company’s stock, valued at $12,663,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $54.66, for a total value of $273,300.00. Following the sale, the chief executive officer now directly owns 235,000 shares in the company, valued at approximately $12,845,100. The disclosure for this sale can be found here. 9.60% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of the company. FMR LLC increased its stake in shares of Spark Therapeutics by 10.6% in the second quarter. FMR LLC now owns 4,499,326 shares of the company’s stock worth $230,051,000 after buying an additional 432,868 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Spark Therapeutics by 9.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,906,496 shares of the company’s stock worth $174,564,000 after buying an additional 248,309 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Spark Therapeutics by 28.9% in the second quarter. Vanguard Group Inc. now owns 1,512,600 shares of the company’s stock worth $77,340,000 after buying an additional 338,720 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Spark Therapeutics during the third quarter worth about $79,180,000. Finally, Lord Abbett & CO. LLC increased its stake in shares of Spark Therapeutics by 182.9% in the second quarter. Lord Abbett & CO. LLC now owns 1,165,207 shares of the company’s stock worth $59,577,000 after buying an additional 753,377 shares in the last quarter. 82.98% of the stock is currently owned by institutional investors and hedge funds.
About Spark Therapeutics
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.